See more : Kodal Minerals Plc (KOD.L) Income Statement Analysis – Financial Results
Complete financial analysis of Harrow Health, Inc. (HROW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Harrow Health, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Associated British Foods plc (ASBFF) Income Statement Analysis – Financial Results
- Mullen Automotive, Inc. (MULN) Income Statement Analysis – Financial Results
- LeanLife Health Inc. (LNLHF) Income Statement Analysis – Financial Results
- Oscar Properties Holding AB (publ) (OP-PREF.ST) Income Statement Analysis – Financial Results
- Fortescue Metals Group Limited (FSUGY) Income Statement Analysis – Financial Results
Harrow Health, Inc. (HROW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.harrowinc.com
About Harrow Health, Inc.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.19M | 88.60M | 72.48M | 48.87M | 51.17M | 41.37M | 26.77M | 19.94M | 9.72M | 1.66M | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.64M | 25.38M | 18.21M | 14.46M | 16.75M | 16.52M | 13.51M | 9.83M | 5.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 90.55M | 63.21M | 54.26M | 34.41M | 34.42M | 24.85M | 13.27M | 10.11M | 4.51M | 567.41K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.55% | 71.35% | 74.87% | 70.41% | 67.26% | 60.07% | 49.56% | 50.70% | 46.42% | 34.18% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.88M | 3.05M | 11.08M | 2.41M | 2.08M | 825.00K | 413.00K | 739.00K | 332.00K | 236.66K | 1.62M | 1.30M | 111.55K | 194.59K | 2.97M | 1.99M | 1.83M | 150.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.96M | 17.57M | 12.50M | 8.09M | 5.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 430.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.06M | 7.38M | 6.50M | 2.39M | 85.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -423.79K |
| SG&A | 83.09M | 58.24M | 41.32M | 31.25M | 33.10M | 29.24M | 25.02M | 24.95M | 19.00M | 10.48M | 6.08M | 2.98M | 827.67K | 2.31M | 1.60M | 1.76M | 2.86M | 6.21K |
| Other Expenses | 0.00 | -15.93M | -19.49M | -3.80M | 630.00K | 103.00K | 0.00 | 1.54M | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -110.00K |
| Operating Expenses | 90.12M | 61.29M | 52.40M | 33.66M | 35.18M | 30.07M | 25.43M | 25.69M | 19.33M | 10.71M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Cost & Expenses | 129.76M | 86.68M | 70.61M | 48.12M | 51.93M | 46.59M | 38.94M | 35.52M | 24.54M | 11.81M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Interest Income | 0.00 | 7.24M | 5.44M | 2.24M | 0.00 | 0.00 | 0.00 | 10.00K | 13.00K | 32.45K | 43.76K | 15.41K | 0.00 | 512.00 | 10.44K | 67.01K | 48.44K | 0.00 |
| Interest Expense | 21.32M | 7.24M | 5.44M | 2.24M | 2.50M | 2.73M | 3.03M | 6.00M | 1.12M | 3.80K | 0.00 | 24.66K | 75.00K | 55.48K | 0.00 | 0.00 | 1.56M | -10.00K |
| Depreciation & Amortization | 12.34M | 3.67M | 2.40M | 2.74M | 2.66M | 1.84M | 1.77M | 1.41M | 610.00K | 85.35K | 5.66K | 2.94K | 338.00 | 1.06K | 1.06K | 704.00 | 201.25K | 0.00 |
| EBITDA | 9.72M | -3.20M | -10.14M | 3.49M | 1.44M | -2.73M | -10.40M | -14.06M | -14.21M | -10.06M | -7.64M | -5.36M | -878.60K | -2.47M | -4.55M | -4.12M | -2.75M | -46.21K |
| EBITDA Ratio | 7.47% | 2.17% | 2.91% | 2.27% | 4.22% | -7.21% | -55.59% | -59.13% | -146.27% | -604.06% | -76,374.65% | -4,160.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 431.00K | -1.75M | -284.00K | -1.63M | -503.00K | -5.22M | -12.16M | -15.88M | -14.82M | -10.15M | -7.69M | -4.18M | -939.23K | -2.50M | -4.56M | -3.75M | -2.86M | -46.21K |
| Operating Income Ratio | 0.33% | -1.97% | -0.39% | -3.34% | -0.98% | -12.61% | -45.43% | -79.64% | -152.55% | -611.16% | -76,868.79% | -4,178.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -24.37M | -15.93M | -19.49M | -3.80M | 386.00K | 19.84M | -757.00K | -3.32M | -1.08M | 28.65K | 43.76K | -1.20M | -14.71K | -28.67K | 10.44K | 375.00K | -1.43M | -533.79K |
| Income Before Tax | -23.94M | -14.01M | -17.87M | -3.42M | -125.00K | 14.63M | -12.92M | -19.20M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | 0.00 | -3.37M | -2.77M | -580.00K |
| Income Before Tax Ratio | -18.39% | -15.81% | -24.66% | -6.99% | -0.24% | 35.35% | -48.26% | -96.27% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 470.00K | 75.00K | 133.00K | 4.00K | 2.47M | -19.45M | -935.00K | -111.00K | 1.08M | -28.65K | -43.76K | 1.20M | -60.29K | -26.30K | -10.44K | -817.01K | -228.27K | 10.00K |
| Net Income | -24.41M | -14.09M | -18.01M | -3.42M | -2.59M | 14.63M | -11.99M | -19.09M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | -4.55M | -3.30M | -4.28M | -46.21K |
| Net Income Ratio | -18.75% | -15.90% | -24.85% | -7.00% | -5.07% | 35.35% | -44.76% | -95.71% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| EPS Diluted | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| Weighted Avg Shares Out | 32.62M | 27.46M | 26.76M | 25.90M | 25.32M | 23.81M | 19.98M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
| Weighted Avg Shares Out (Dil) | 32.62M | 27.46M | 26.76M | 25.90M | 26.47M | 23.81M | 20.03M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
Wall Street Analysts Believe Harrow (HROW) Could Rally 25.95%: Here's is How to Trade
Best Momentum Stocks to Buy for October 24th
New Strong Buy Stocks for October 24th
Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why
I Am Banking On The Silver Tsunami With Big Dividends
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
Harrow Relaunches TRIESENCE®
Harrow Inc (HROW) Shares Up 3.26% on Oct 2
Harrow Announces Nashville Expansion
Harrow to Present at Three Investor Conferences in September in New York
Source: https://incomestatements.info
Category: Stock Reports